4,795 reports of this reaction
10.3% of all EMTRICITABINE AND TENOFOVIR ALAFENAMIDE reports
#1 most reported adverse reaction
BONE DENSITY DECREASED is the #1 most commonly reported adverse reaction for EMTRICITABINE AND TENOFOVIR ALAFENAMIDE, manufactured by Gilead Sciences, Inc.. There are 4,795 FDA adverse event reports linking EMTRICITABINE AND TENOFOVIR ALAFENAMIDE to BONE DENSITY DECREASED. This represents approximately 10.3% of all 46,639 adverse event reports for this drug.
Patients taking EMTRICITABINE AND TENOFOVIR ALAFENAMIDE who experience bone density decreased should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
BONE DENSITY DECREASED is a frequently reported adverse event for EMTRICITABINE AND TENOFOVIR ALAFENAMIDE, accounting for a significant proportion of all reports.
In addition to bone density decreased, the following adverse reactions have been reported for EMTRICITABINE AND TENOFOVIR ALAFENAMIDE:
The following drugs have also been linked to bone density decreased in FDA adverse event reports:
BONE DENSITY DECREASED has been reported as an adverse event in 4,795 FDA reports for EMTRICITABINE AND TENOFOVIR ALAFENAMIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
BONE DENSITY DECREASED accounts for approximately 10.3% of all adverse event reports for EMTRICITABINE AND TENOFOVIR ALAFENAMIDE, making it one of the most commonly reported side effect.
If you experience bone density decreased while taking EMTRICITABINE AND TENOFOVIR ALAFENAMIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.